Research Grade Naxitamab (DGK07803)

Catalog No.

DGK07803

Expression system

Mammalian Cells

Species reactivity

General

Host species

Chimeric

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

Ganglioside GD2

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

CAS: 65988-71-8

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

Hu3F8, Naxitamab-gqgk, CAS: 1879925-92-4

Clone ID

Naxitamab

Naxitamab, PMID: 33355727

Naxitamab-gqgk, PMID: 33684934

Naxitamab: First Approval, PMID: 33616889

Survival Impact of Anti-GD2 Antibody Response in a Phase II Ganglioside Vaccine Trial Among Patients With High-Risk Neuroblastoma With Prior Disease Progression, PMID: 33326254

Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remission, PMID: 34022112

The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies, PMID: 33324208

Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma, PMID: 33809255

Document Download

Research Grade Naxitamab.pdf